Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.95 +1.6%	$1.71	$1.33 ▼ $3.58	$90.45M	0.74	61,241 shs	4,535 shs
COYA Coya Therapeutics	$5.51 +3.6%	$5.80	$4.65 ▼ $10.24	$88.98M	0.21	71,140 shs	46,605 shs
MIST Milestone Pharmaceuticals	$1.72 -0.6%	$1.34	$0.63 ▼ $2.75	$92.49M	0.92	932,153 shs	562,341 shs
NNVC NanoViricides	$1.34	$1.41	$0.94 ▼ $2.55	$21.54M	0.91	238,259 shs	121,624 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+1.56%	-1.52%	+10.17%	+9.55%	-25.29%
COYA Coya Therapeutics	+3.57%	-2.13%	-7.71%	-14.84%	-15.03%
MIST Milestone Pharmaceuticals	-0.58%	0.00%	+33.33%	-11.79%	+23.74%
NNVC NanoViricides	0.00%	-11.84%	-8.22%	+1.52%	-19.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
ADAG Adagene	2.5655 of 5 stars	3.3	5.0	0.0	1.7
COYA Coya Therapeutics	2.0831 of 5 stars	3.5	4.0	1.3	0.8
MIST Milestone Pharmaceuticals	2.1761 of 5 stars	3.2	3.0	1.9	2.5
NNVC NanoViricides	0.1329 of 5 stars	0.0	3.0	1.1	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	310.26% Upside
COYA Coya Therapeutics	3.00	Buy	$16.67	202.48% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	306.98% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NNVC, MIST, ADAG, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/3/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/1/2025	MIST Milestone Pharmaceuticals	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/28/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	918.65	N/A	N/A	$1.14 per share	1.71
COYA Coya Therapeutics	$3.55M	25.97	N/A	N/A	$2.37 per share	2.32
MIST Milestone Pharmaceuticals	$1M	91.95	N/A	N/A	$0.25 per share	6.88
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A

Latest NNVC, MIST, ADAG, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
COYA Coya Therapeutics	N/A	8.84	8.84
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
COYA Coya Therapeutics	39.75%
MIST Milestone Pharmaceuticals	86.18%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
COYA Coya Therapeutics	12.00%
MIST Milestone Pharmaceuticals	19.50%
NNVC NanoViricides	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable

NNVC, MIST, ADAG, and COYA Headlines

Recent News About These Companies

NanoViricides touts antiviral NV-387 as tool against new COVID variant

June 18 at 8:36 AM | proactiveinvestors.com

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

June 18 at 6:30 AM | accessnewswire.com

NanoViricides measles drug development animal study imminent

June 4, 2025 | msn.com

NanoViricides commissions animal study of broad-spectrum antiviral for measles

June 4, 2025 | proactiveinvestors.com

NanoViricides Measles Drug Development Animal Study is Imminent

June 4, 2025 | accessnewswire.com

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025 | accessnewswire.com

NanoViricides president backs FDA's targeted COVID booster policy shift

May 22, 2025 | proactiveinvestors.com

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides’ Dr. Diwan

May 22, 2025 | miamiherald.com

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025 | accessnewswire.com

NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox

May 16, 2025 | proactiveinvestors.com

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 15, 2025 | star-telegram.com

NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 15, 2025 | finanznachrichten.de

NanoViricides progresses antiviral portfolio as measles and MPox threats rise

May 14, 2025 | proactiveinvestors.com

NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC

May 8, 2025 | proactiveinvestors.com

NanoViricides, Inc. Announces Participation in the D. ...

May 5, 2025 | gurufocus.com

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025 | newsfilecorp.com

NanoViricides advances measles drug development amid rising US cases

April 29, 2025 | proactiveinvestors.com

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

April 29, 2025 | accessnewswire.com

NanoViricides evaluating antiviral drug NV-387 for measles treatment

April 14, 2025 | proactiveinvestors.com

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

April 14, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
By Thomas Hughes | May 29, 2025
View Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
GameStop Buys Bitcoin: Smart Strategy or Big Mistake?
By Thomas Hughes | May 28, 2025
View GameStop Buys Bitcoin: Smart Strategy or Big Mistake?

NNVC, MIST, ADAG, and COYA Company Descriptions

Adagene NASDAQ:ADAG

$1.95 +0.03 (+1.56%)

Closing price 06/18/2025 03:56 PM Eastern

Extended Trading

$1.98 +0.03 (+1.54%)

As of 06/18/2025 04:59 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Coya Therapeutics NASDAQ:COYA

$5.51 +0.19 (+3.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.61 +0.10 (+1.89%)

As of 06/18/2025 04:22 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Milestone Pharmaceuticals NASDAQ:MIST

$1.72 -0.01 (-0.58%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.72 0.00 (0.00%)

As of 06/18/2025 07:58 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

NanoViricides NYSE:NNVC

$1.34 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.01 (+0.82%)

As of 06/18/2025 08:00 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time